Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from Atripla to Odefsey-like FTC/RPV/TAF in virologically suppressed HIV-1
NL-OMON42500Phase 3Withdrawn
- Sponsor
- Gilead Sciences
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rilpivirine, tenofovir alafenamide, emtricitabine, efavirenz and tenofovir disoproxil fumarate in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: Proportion with HIV-1 RNA <50 copies/mL at Week 48. Planned start Mar 2015; status: withdrawn.
02
Drugs
rilpivirinetenofovir alafenamideemtricitabineefavirenztenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON42500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42500.